Study gut microbes with immune therapy in several solid cancers
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have one of these cancers: lung (NSCLC), melanoma (MM), triple-negative breast cancer (TNBC), or kidney cancer (RCC), in stages I–IV
- Your cancer care plan includes a checkpoint inhibitor (anti–PD-1, anti–PD-L1, or anti–CTLA-4), either alone or with other approved treatments
- You can give informed consent and complete questionnaires in English or Spanish
- You can provide stool samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.